TGX-<wbr/>221

TGX-221

CAT N°: 10007349
Price:

From 48.00 40.80

Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of phosphatidylinositol at the 3 position to produce the second messengers phosphatidylinositol-3,4-bisphosphate (PtdIns-(3,4)-P2) and PtdIns-(3,4,5)-P3.{8039,12235,13740} Class 1 PI3Ks are composed of a p110 catalytic subunit, of which there are 4 isoforms (p110?, p110?, p110?, and p100?), and a p85 regulatory subunit.{13740} TGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110?.{13192} Inhibition appears to occur at the ATP binding site based on the observed increase in IC50 value from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively. TGX-221 inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM.{13192} Selective inhibition of PI3K p110? results in defective platelet thrombus formation and defines PI3K as a target for antithrombotic therapy.{13192}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one
  • Correlated keywords
    • phosphatidylinositol-3-kinases PI3K catalyzes phosphorylation produces second messengers (3,4)-biphosphates -P2 (3,4,5)-P3 Class 1 p110.alpha. .beta. .delta. .gamma. p85 regulatory subunits cells permeable inhibitors inhibition inhibits ATP binding sites platelets defective thrombus formation antithrombotic therapy atherosclerosis
  • Product Overview:
    Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of phosphatidylinositol at the 3 position to produce the second messengers phosphatidylinositol-3,4-bisphosphate (PtdIns-(3,4)-P2) and PtdIns-(3,4,5)-P3.{8039,12235,13740} Class 1 PI3Ks are composed of a p110 catalytic subunit, of which there are 4 isoforms (p110?, p110?, p110?, and p100?), and a p85 regulatory subunit.{13740} TGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110?.{13192} Inhibition appears to occur at the ATP binding site based on the observed increase in IC50 value from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively. TGX-221 inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM.{13192} Selective inhibition of PI3K p110? results in defective platelet thrombus formation and defines PI3K as a target for antithrombotic therapy.{13192}

We also advise you